<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00478062</url>
  </required_header>
  <id_info>
    <org_study_id>J06143 CDR0000544408</org_study_id>
    <secondary_id>P50CA096888</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J06143</secondary_id>
    <secondary_id>JHOC-NA_00007920</secondary_id>
    <nct_id>NCT00478062</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma</brief_title>
  <official_title>KGEL Vaccine After Initial Therapy of Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a tumor antigen may help the body build an effective immune
      response to kill tumor cells.

      PURPOSE: This phase I/II trial is studying the side effects and how well vaccine therapy
      works in treating patients who have received first-line therapy for Hodgkin's lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine immunologic responses in patients who have completed first-line therapy for
           Hodgkin's lymphoma treated with Hodgkin's antigens-GM-CSF-expressing cell vaccine.

        -  Determine the durability of these immunologic responses in these patients.

        -  Determine the utility of an Epstein-Barr virus reporter system for monitoring cellular
           vaccine responses.

        -  Determine the safety and tolerability of this vaccine in these patients.

      OUTLINE: Beginning 4-6 months after last chemotherapy, patients receive Hodgkin's
      antigens-GM-CSF-expressing cell vaccine on day 1. Treatment repeats every 3 weeks for up to 4
      courses.

      Immunologic responses are serially monitored along with disease status.

      PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual
  </why_stopped>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunologic Response</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Durability of Immunologic Response</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Utility of Epstein-Barr Virus Reporter System for Monitoring Cellular Vaccine Responses</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>After administration of last vaccine at 9 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Cell vaccine after initial therapy for Hodgkin lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hodgkin's antigens-GM-CSF-expressing cell vaccine after initial therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hodgkin's antigens-GM-CSF-expressing cell vaccine</intervention_name>
    <arm_group_label>Cell vaccine after initial therapy for Hodgkin lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <arm_group_label>Cell vaccine after initial therapy for Hodgkin lymphoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of classic Hodgkin's lymphoma

          -  Must have completed first-line therapy without evidence of disease progression

        PATIENT CHARACTERISTICS:

          -  HIV negative

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No more than 6 months since prior chemotherapy or radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvette L. Kasamon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2007</study_first_submitted>
  <study_first_submitted_qc>May 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2007</study_first_posted>
  <results_first_submitted>January 31, 2018</results_first_submitted>
  <results_first_submitted_qc>January 31, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 28, 2018</results_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I adult Hodgkin lymphoma</keyword>
  <keyword>stage II adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cell Vaccine After Initial Therapy for Hodgkin Lymphoma</title>
          <description>Hodgkin's antigens-GM-CSF-expressing cell vaccine after initial therapy.
Hodgkin's antigens-GM-CSF-expressing cell vaccine
adjuvant therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cell Vaccine After Initial Therapy for Hodgkin Lymphoma</title>
          <description>Hodgkin's antigens-GM-CSF-expressing cell vaccine after initial therapy.
Hodgkin's antigens-GM-CSF-expressing cell vaccine
adjuvant therapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Immunologic Response</title>
        <time_frame>9 months</time_frame>
        <population>The study was closed due to slow accrual, with only one patient enrolled. No data was analyzed for any outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Cell Vaccine After Initial Therapy for Hodgkin Lymphoma</title>
            <description>Hodgkin's antigens-GM-CSF-expressing cell vaccine after initial therapy.
Hodgkin's antigens-GM-CSF-expressing cell vaccine
adjuvant therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Immunologic Response</title>
          <population>The study was closed due to slow accrual, with only one patient enrolled. No data was analyzed for any outcome measures.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Durability of Immunologic Response</title>
        <time_frame>2 years</time_frame>
        <population>The study was closed due to slow accrual, with only one patient enrolled. No data was analyzed for any outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Cell Vaccine After Initial Therapy for Hodgkin Lymphoma</title>
            <description>Hodgkin's antigens-GM-CSF-expressing cell vaccine after initial therapy.
Hodgkin's antigens-GM-CSF-expressing cell vaccine
adjuvant therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Durability of Immunologic Response</title>
          <population>The study was closed due to slow accrual, with only one patient enrolled. No data was analyzed for any outcome measures.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Utility of Epstein-Barr Virus Reporter System for Monitoring Cellular Vaccine Responses</title>
        <time_frame>2 years</time_frame>
        <population>The study was closed due to slow accrual, with only one patient enrolled. No data was analyzed for any outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Cell Vaccine After Initial Therapy for Hodgkin Lymphoma</title>
            <description>Hodgkin's antigens-GM-CSF-expressing cell vaccine after initial therapy.
Hodgkin's antigens-GM-CSF-expressing cell vaccine
adjuvant therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Utility of Epstein-Barr Virus Reporter System for Monitoring Cellular Vaccine Responses</title>
          <population>The study was closed due to slow accrual, with only one patient enrolled. No data was analyzed for any outcome measures.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability</title>
        <time_frame>After administration of last vaccine at 9 weeks</time_frame>
        <population>The study was closed due to slow accrual, with only one patient enrolled. No data was analyzed for any outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Cell Vaccine After Initial Therapy for Hodgkin Lymphoma</title>
            <description>Hodgkin's antigens-GM-CSF-expressing cell vaccine after initial therapy.
Hodgkin's antigens-GM-CSF-expressing cell vaccine
adjuvant therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability</title>
          <population>The study was closed due to slow accrual, with only one patient enrolled. No data was analyzed for any outcome measures.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cell Vaccine After Initial Therapy for Hodgkin Lymphoma</title>
          <description>Hodgkin's antigens-GM-CSF-expressing cell vaccine after initial therapy.
Hodgkin's antigens-GM-CSF-expressing cell vaccine
adjuvant therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yvette Kasamon</name_or_title>
      <organization>Johns Hopkins Sidney Kimmel Cancer Center</organization>
      <phone>4109135018</phone>
      <email>ykasamon@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

